使用适形支架移植物治疗急性复杂性B型主动脉夹层的五年结局多中心临床试验
这项前瞻性非随机多中心研究纳入美国26个中心的50例急性复杂性B型主动脉夹层患者,评估使用GORE适形TAG胸主动脉内假体行胸主动脉腔内修复术(TEVAR)的5年结局。5年全因死亡率为26%,主动脉病变相关晚期死亡占4%,22%的患者需要二次干预,87%的患者观察到支架移植物旁假腔完全血栓形成,真腔最大直径显著增加11 mm、假腔最大直径显著减少22 mm,作者认为该装置具有安全性、有效性和长期耐久性。
要点
- 5年全因死亡率为26%,主动脉病变相关晚期死亡占4%。
- 22%的患者需要二次干预,87%的患者支架旁假腔完全血栓形成。
- 5年真腔最大直径增加11 mm、假腔最大直径减少22 mm,均P<0.0001。
核心结论
- 作者认为,对具有晚期病理生理特征的患者使用CTAG装置治疗可获得良好的长期临床和解剖结局,假腔完全血栓形成和正向主动脉重塑在整个研究期间持续存在,晚期主动脉事件发生率低,表明该装置具有安全性、有效性和长期耐久性。
研究设计与样本
- 前瞻性、非随机研究,2010年1月至2017年2月从美国26个中心纳入50例急性复杂性B型主动脉夹层患者。
- 患者术后、1个月、6个月、1年及此后每年随访至5年,CT扫描由核心实验室评估装置相关事件、假腔血栓形成和主动脉重塑。
主要发现
- 5年全因死亡率为26%。
- 4%的患者发生归因于主动脉病理的晚期(>30天)死亡。
- 22%的患者需要二次干预。
- 87%的患者观察到与支架移植物平行的假腔部分完全血栓形成。
- 5年间真腔最大直径显著增加11 mm(P<0.0001),假腔最大直径显著减少22 mm(P<0.0001),真腔面积增加221 mm²(P=0.0003),假腔面积无显著变化。
关键数值与推荐
- 未观察到患者结局与治疗前指征(即破裂伴或不伴灌注不良,或单纯灌注不良)之间存在关联。
临床怎么用
- 作者认为,对具有晚期病理生理特征的患者使用CTAG装置治疗可获得良好的长期临床和解剖结局,假腔完全血栓形成和正向主动脉重塑持续存在,晚期主动脉事件发生率低,表明该装置具有安全性、有效性和长期耐久性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thoracic endovascular aortic repair (TEVAR) has become the treatment of choice for acute, complicated type B aortic dissections. The purpose of this study was to evaluate the 5-year outcomes of the GORE thoracic aortic graft (TAG) 08-01 study on TEVAR for acute, complicated type B aortic dissections using the GORE conformable TAG thoracic endoprosthesis (CTAG) and to establish if late aortic complications are avoided and remodeling is sustained. METHODS: From January 2010 to February 2017, 50 patients with acute, complicated type B aortic dissections were enrolled from 26 sites in the United States in this prospective, nonrandomized study. Patients underwent follow-up assessments postprocedure, at 1 month, 6 months, 1 year, and then yearly through 5 years. Device-related events, false lumen thrombosis, and aortic remodeling were assessed from computed tomography (CT) scans by a core laboratory. RESULTS: The all-cause mortality rate through 5 years was 26%. 4% of patients experienced late (>30 day) deaths that were attributable to aortic pathology. Secondary interventions were required in 22% of patients. In 87% of patients, complete false lumen thrombosis in the portion of the false lumen parallel to the stent-graft was observed. There was a significant 11 mm increase in the maximum true lumen diameter (P < 0.0001) and a 22 mm decrease in the maximum false lumen diameter (P < 0.0001) over 5 years. True lumen area was also increased by 221 mm2 (P = 0.0003) over 5 years. There was no significant change in the false lumen area. There were no associations observed between patient outcomes and pretreatment indication for treatment (i.e., rupture with or without malperfusion or malperfusion alone). CONCLUSIONS: Treatment of patients with advanced pathophysiology with the CTAG device resulted in favorable long-term clinical and anatomic outcomes. Complete thrombosis of the false lumen and positive aortic remodeling was sustained throughout the study. The low rate of late aortic events observed in this study demonstrates the safety, effectiveness, and the long-term durability of the CTAG device.
引用
- Desai N, Tohill B, Matsumura J, et al. A Multicenter Clinical Trial on the Five-Year Outcomes Following Treatment of Acute, Complicated Type B Aortic Dissection With a Conformable Stent Graft. Ann Vasc Surg. 2024. PMID: 39694187. doi:10.1016/j.avsg.2024.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。